In contrast, treatment of glioma cells with STS66 (60 μM) alone or TMZ plus STS66 for 24 or 48 h significantly reduced glioma cells proliferation and induced G0/G1 arrest, which appears to correlate with NKCC1-mediated reduced K+ influx. The gene discussed is SLC12A2; the disease is central nervous system cancer.